| Tata India Pharma And Healthcare Fund |  |
As on 30th September 2026
|
Type of Scheme: Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of
the companies in the Pharma & Healthcare sectors in India.
Product labelling: • Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
• Long Term Capital Appreciation.
Product labelling: • Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
• Long Term Capital Appreciation.
Date of Inception / Allotment
Fund Manager Details
Minimum Investment
Load Structure
Scheme Riskometer
Tata India Pharma And Healthcare Fund
Benchmark Riskometer
BSE HC TRI
28 December 2015
Benchmark NameBSE HC TRI
NAV as on September 30,2026| Regular Plan - Growth Option | ₹ 32.3705 |
| Regular Plan - IDCW Option | ₹ 31.1321 |
| Direct Plan - Growth Option | ₹ 38.3028 |
| Direct Plan - IDCW Option | ₹ 37.0578 |
| | |
| AUM as on September 30,2026 | : ₹ 1,511.49 Cr |
| AAUM as on September 30,2026 | : ₹ 1,547.79 Cr |
Fund Manager Details
Name of Fund Managers
• Mr. Rajat Srivastava
| Total Experience | : | 9 |
| Managing Since | : | 16-Sep-2024 |
| Lumpsum Amount | : | Rs. 5,000/- and in multiples of Re. 1/- thereafter. |
| SIP | : | Rs. 100/- and in multiples of Re. 1/- thereafter. |
Exit Load:0.25% of NAV if redeemed/switched out on or before 30 days from the date of allotment.
Base Expense Ratio**| Regular plan : | : 1.80% | ||
| Direct plan : | : 0.63% | ||
| Risk Measures* | ||
| 1 | Standard Deviation (%) | 16.71 |
| 2 | Beta | 0.97 |
| 3 | Tracking Error (%) | |
| 1 year | NA | |
| 3 years | NA | |
| 4 | Sharpe Ratio (%) | 0.71 |
| 5 | Tracking Difference (%) | |
| 1 year | NA | |
| 3 year | NA | |
| 5 year | NA | |
| Since Inception | NA | |
| 6 | Information Ratio | NA |
|
* Please refer detail description in Description/inference of the Quantitative/Risk Measures
in tabular format
NA stands for “Not Applicable” **Note: The rates specified are actual month end BER charged as on 30th Sep 2026. The above ratio excludes other expenses charged under TER. For more details kindly refer to the TER disclosure on website. https://www.tatamutualfund.com/expenseratio/ total-expense-ratio | ||
| Compounded Annualised Returns | Scheme Returns % - Regular | Scheme Returns % - Direct | Benchmark Returns % |
| Returns for last 1 year | 7.91 | 9.46 | 16.77 |
| Returns for last 3 years | 16.76 | 18.48 | 21.25 |
| Returns for last 5 years | 12.64 | 14.32 | 14.60 |
| Returns since inception | 11.53 | 13.29 | 11.28 |
Performance as on September 30,2026.
| Top 10 Holdings | % to Net Assets | |
| 1 | Sun Pharmaceutical Industries Ltd. | 7.99% |
| 2 | Abbott India Ltd. | 5.94% |
| 3 | Healthcare Global Enterprises Ltd. | 5.92% |
| 4 | Divi Laboratories Ltd. | 5.68% |
| 5 | Dr. Reddys Labaratories Ltd. | 4.65% |
| 6 | Apollo Hospitals Enterprise Ltd. | 4.36% |
| 7 | Rainbow Childrens Medicare Ltd. | 4.30% |
| 8 | Cipla Ltd. | 4.22% |
| 9 | Torrent Pharmaceuticals Ltd. | 3.76% |
| 10 | Max Healthcare Institute Ltd. | 3.71% |
| 1 | Portfolio Turnover Ratio (Annualized) | |
| a) Equity Turnover (%) | 106.75 | |
| b) Gross Exposure Turnover (%) | 106.75 | |
| (Equity + Debt + Derivatives) | ||
| 2 | Average Maturity (years): | NA |
| 3 | Macaulay Duration (years): | NA |
| 4 | Modified Duration (years): | NA |
| 5 | Annualized Portfolio Yield: | NA |
| 6 | Yield to Maturity (%) | NA |
* Please refer detail description in Description/inference of the Quantitative/Risk Measures
in tabular format
NA stands for “Not Applicable”
| 1 | Sector bias | |
| 2 | Regulatory hurdles | |
| 3 | R & D reliance | |
| 4 | valuation stretch |
*with a detailed explanation in the Important Link Section
Tata India Pharma And Healthcare Fund
Benchmark Riskometer
BSE HC TRI
| Detailed Investment in Securities |  |
| Allocation of Net Asset by Sectors | |
| Allocation of Net Asset by Asset Class | |
| Allocation of Net Assets by Credit Rating | |
| Allocation of Net Assets by region/country | |
Major Changes w.r.t previous month –
| Name of securities added | Name of securities deleted/reduced | Total Weightage in % |
| Fortis Healthcare Ltd. | 3.30% | |
| Acutaas Chemicals Ltd. | 1.95% | |
| Global Health Ltd. | 1.68% | |
| Natco Pharma Ltd. | 1.51% | |
| Navin Fluorine International Ltd. | Ami Organics Ltd. | 1.48% |
| 1.18% | ||
| Prasol Chemicals Ltd. | Metropolis Healthcare Ltd. | 1.11% |
| Gujarat Fluorochemicals Ltd. | 0.88% | |
| 0.53% | ||
| HDFC Life Insurance Company Ltd. | 0.50% |
| Change in | Previous Month | Current Month |
| Direct | 0.62% | 0.63% |
| Regular | 1.80% | 1.80% |
| Name of security |
Rating Previous Month |
Rating Current Month |
| NA | NA | NA |
| Fund Name | Previous Month | Current Month |
| Scheme Riskometer | Very High | Very High |
| Sr. No. | Quantitative Measures/Risk Measures | Brief description/ Inference of the Quantitative measure |
| 1 | Standard Deviation | Measures the volatility of the fund |
| 2 | Beta | Shows fund's sensitivity to market movements |
| 3 | Sharpe Ratio | Evaluates the excess return generated per unit of risk |
| 4 | Tracking Error | Indicates how closely fund tracks the Benchmark |
| 5 | Tracking Difference | Difference between the fund and its benchmark return |
| 6 | Portfolio Turnover Ratio | Indicates how actively the portfolio changes |
| 7 | Average Maturity | Weighted average residual maturity |
| 8 | Macaulay Duration | Fund's sensitivity to interest rate changes |
| 9 | Modified Duration | Fund's sensitivity to interest rate changes |
| 10 | Annualized Portfolio Yield | Total income generated by the portfolio |
| 11 | Yield to Maturity | weighted average expected annual return |
| Sr. No. | Links | Description |
| 1 | Video Explainer | Link for a video providing simplified explanation of the Fund Factsheet along with explanation to various terminologies used. |
| 2 | Calculation/Methodology | Link for a pdf showing the various mathematical parameters and their respective Calculation methodology/formulae along with any assumptions considered. |
| 3 | Detailed Risk Factors | Link to be provided for various risk factors associated with the Scheme. |
| 4 |  | Link for SID on AMC website. |
| 5 | Investor Services | Link showing Contact details (Email ID and Telephone Number of the Investor). |
| 6 | Grievance submission and redressal | Link directing to grievance submission page with details showing Escalation matrix. |
Additional Disclosure by AMC
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related
instruments of the companies in the pharma & healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of
the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
| Large Cap | 26.09% |
| Mid Cap | 34.56% |
| Small Cap | 39.36% |
| Market Capitalisation is as per list provided by AMFI. | |
Past Performance is not an indicator or guarantee of future results